GlassScriptPhysician profile
Douglas B Deyoung
NPI 1811989064
$1,418.88
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $176 · 2021: $432 · 2022: $310 · 2023: $16.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $345.78 | 2019-2022 | |
| Abiomed | $114.82 | 2021 | |
| Novartis Pharmaceuticals Corporation | $100.42 | 2019 | |
| Lilly USA, LLC | $86.83 | 2019-2022 | |
| Daiichi Sankyo INC. | $75.43 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $75.24 | 2019 | |
| Glaxosmithkline, LLC. | $60.73 | 2019-2022 | |
| Amgen INC. | $59.56 | 2019-2023 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $51.47 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $42.59 | 2019 | |
| Nestle Healthcare Nutrition INC. | $39.89 | 2022 | |
| Therapeuticsmd, INC. | $32.47 | 2019-2021 | |
| Mylan Specialty L.P. | $29.97 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.67 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.14 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $29.04 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.87 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.71 | 2019-2020 | |
| Allergan, INC. | $24.34 | 2020 | |
| Optinose US, INC. | $24.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $21.18 | 2019 | |
| Bioventus LLC | $19.58 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.35 | 2020 | |
| Pfizer INC. | $14.70 | 2019 | |
| Sanofi Pasteur INC. | $14.17 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.12 | 2019 | |
| Novo Nordisk INC | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Deyoung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.